Back to search

Article

Myelosuppression in a Metastatic Breast Cancer Patient with GSTP1 rs1695 Mutation Induced by Adriamycin and Cyclophosphamide

2024-11-25

Abstract excerpt

<h4>Introduction: </h4> Adriamycin and cyclophosphamide (AC) combination chemotherapy is one of the common regimens used for breast cancer and in metastatic breast cancer with oligo-metastasis. (1) AC combination chemotherapy regimen is associated with adverse drug reactions like myelosuppression, gastrointestinal toxicity, cardiotoxicity, peripheral neuropathy, and hand-foot syndrome. (2),(3),(4) It has been noti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8cd61d00-46fb-584c-b699-101af5a5d050
DOI
10.22541/au.173253097.70707711/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Myelosuppression in a Metastatic Breast Cancer Patient with GSTP1 rs1695 Mutation Induced by Adriamycin and CyclophosphamideDOI 10.22541/au.173253097.70707711/v1
Select a neighboring publication to make it the new centre.